NewAmsterdam Pharma N.V. Announces First Patient Dosed in Phase 2b Trial

What Happened On September 29, 2026, NewAmsterdam Pharma Company N.V. announced that the first patient was dosed in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. The company filed a press release about the event as Exhibit 99.1 to its Form 8-K (Item 8.01), and the report was signed by Mike Marino, Chief Legal Officer.

Key Details

• Date announced: September 29, 2026 (Form 8-K filed same day).
• Trial: SPINOZA, Phase 2b clinical study of obicetrapib.
• Milestone: First patient dosed (clinical trial progression).
• Filing: Press release included as Exhibit 99.1 to the Form 8-K; report signed by Mike Marino.

Why It Matters Dosing the first patient is a key operational milestone showing the SPINOZA study has moved from planning into active patient enrollment and testing. For investors, this indicates progress in NewAmsterdam’s clinical development program for obicetrapib in a neurodegenerative indication; such milestones can affect program timelines, upcoming data-readout expectations, and potential valuation catalysts. The filing itself is informational—no financial results or management changes were reported.